This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 28 open trials
bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
bb2121 (bb2121 CAR-T cells)
Relapsed, Refractory, High risk myeloma
This trial is investigating whether bb2121, a type of treatment known as chimeric antigen receptor T cell (CAR T Cell) therapy, is safe and effective for the treatment of relapsed/refractory and high-risk myeloma patients.
King's College Hospital, London
Who can enter the study?:
Prior to treatment patients undergo leukapheresis (T cell harvest). The harvested T cells are then modified to become the bb2121 treatment.
Patients will then receive the bb2121 treatment by intravenous infusion.
Patients are required to attend outpatient clinics for regular check-ups and tests.
(for Medical Professionals):
This trial is a multi-cohort, open-label, multicenter Phase II trial to evaluate the efficacy and safety of bb2121 in patients with relapsed/refractory myeloma who have either received three prior lines of treatment or are high risk and have relapsed early after one prior line of treatment.
For more information, click here.